Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03050450 · ClinicalTrials.gov registry record · Phase 1
Study of Lenalidomide With Vorinostat in Pediatric Patients With High Grade or Progressive CNS Tumors
A Phase 1 study, sponsored by Johns Hopkins All Children's Hospital.
- Terminated
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT03050450 is a Phase 1 study that was terminated before completion, run by Johns Hopkins All Children's Hospital. The registered enrollment target is 8 participants.
The verdict
NCT03050450, a Phase 1 study, was terminated before completion, sponsored by Johns Hopkins All Children's Hospital.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
Independently, both lenalidomide and vorinostat have shown promising activity in pediatric central nervous system (CNS) tumors. These are both agents that are not typically part of first-line studies, although both agents are of serious interest and are currently in clinical trials for further investigation. This study is to evaluate the combination of lenalidomide and vorinostat in high grade or progressive central nervous system tumors in children.
Interventions
- DRUG 25 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®)
- DRUG 50 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®)
- DRUG 100 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®)
- DRUG 150 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®)
- DRUG 150 mg/m2 Lenalidomide (Revlimid®) and 230 mg/m2 Vorinostat (Zolinza®)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2016-08-10 |
| Est. Completion | 2018-12-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03050450
The ClinicalTrials.gov registry entry for NCT03050450 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins All Children's Hospital, which has 24 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which 25 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®) is the first listed.
NCT03050450 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03050450 about?
NCT03050450 is a clinical study titled "Study of Lenalidomide With Vorinostat in Pediatric Patients With High Grade or Progressive CNS Tumors". Independently, both lenalidomide and vorinostat have shown promising activity in pediatric central nervous system (CNS) tumors. These are both agents that are not typically part of first-line studies, although both agents are of serious interest and are currently in clinical trials for further inves...
What is the current status of trial NCT03050450?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2016-08-10. Estimated completion is 2018-12-19.
What interventions are being tested in trial NCT03050450?
The interventions under investigation include: 25 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®) (DRUG), 50 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®) (DRUG), 100 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®) (DRUG), 150 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®) (DRUG), 150 mg/m2 Lenalidomide (Revlimid®) and 230 mg/m2 Vorinostat (Zolinza®) (DRUG).
Who is sponsoring clinical trial NCT03050450?
This trial is sponsored by Johns Hopkins All Children's Hospital, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.